Question explored with the scientific record
Statins, who should take them and why?
The short version: statins clearly help people who already have heart or artery disease, but for healthy people the benefit is smaller and the decision is a real trade-off.
The strongest case is secondary prevention: people who have already had a heart attack, stroke, or blocked arteries. In older adults with established disease, pravastatin cut the risk of heart death, heart attack, or stroke by about 22% compared to placebo [12]. For people with peripheral artery disease, statins roughly halved the odds of dying from any cause over the study periods, though much of that evidence is observational, not randomized [4]. The 2025 Japanese guidelines push LDL targets below 55 mg/dL after a heart attack, using statins plus ezetimibe or PCSK9 inhibitors [2]. Adding ezetimibe to a statin after a heart attack reduced events in both women and men [6].
For primary prevention, the picture is murkier. The standard risk calculator overestimates risk in many populations, which means it pushes more people onto statins than will ever benefit [13]. A cost-effectiveness model found that for a 57-year-old man at 7.5% ten-year risk, treating everyone without genetic testing was the preferred strategy [1]. But the benefit is modest: each 1 mmol/L drop in LDL cuts major events by about 22% relative, which sounds large until you remember the absolute risk is small to begin with [3]. The benefit also shrinks with higher BMI, with the clearest mortality benefit in people under 25 kg/m² [5].
| Group | Absolute event risk | Statin effect |
|---|---|---|
| Older adults with heart disease | ~22% fewer events | Clear benefit [12] |
| Peripheral artery disease | ~40% lower death odds | Benefit, mostly observational [4] |
| Healthy 57-year-old, 7.5% risk | ~1-2% absolute reduction | Modest, cost-effective to treat all [1] |
| Healthy adults over 75 | No significant event reduction | Unclear benefit [12] |
The side-effect story is more honest than the marketing. In blinded trials, muscle symptoms occur at nearly the same rate with placebo as with statins, and most reported symptoms are nocebo effects [7][9]. But real muscle injury exists, and strenuous exercise may amplify it [10]. A 2025 study mapped exactly how simvastatin binds to the muscle calcium channel, giving a concrete mechanism for genuine muscle damage [11]. New-onset diabetes rises about 0.4-0.6% with high-intensity statins [8].
My call: if you have heart or artery disease, statins are worth it. If you are healthy, the benefit is small enough that lifestyle, BMI, and your own tolerance for daily medication should drive the decision. Confidence: high for secondary prevention, moderate for primary prevention.
Sources used 13
-
Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease
Testing for a 27-SNP cardiovascular genetic risk score is generally not cost-effective for targeting statin therapy in primary prevention of ASCVD in low-to-intermediate-risk patients; treating all is preferred under base case assumptions.
DOI: 10.1161/circoutcomes.117.004171 -
Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report
This Japan Atherosclerosis Society working group conducted a scoping review to define LDL-C treatment targets for secondary prevention across ASCVD categories in Japanese patients, concluding lower targets than prior guidelines (ACS <55 mg/dL; CCS <70 mg/dL; ATBI <70 mg/dL with …
DOI: 10.5551/jat.65908 -
Pharmacological management of atherosclerotic cardiovascular disease risk: a narrative of lipid-lowering pharmacotherapy and the LDL-cholesterol dose-response relationship
Statins remain the cornerstone of ASCVD prevention; intensification with ezetimibe, PCSK9 inhibitors, and bempedoic acid improves LDL-C control, while registries show most high-risk patients still miss guideline targets.
DOI: 10.55529/jpdmhd.51.103.115 -
Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis
A systematic review and meta-analysis showing that statin therapy reduces all-cause mortality and stroke in patients with lower limb peripheral arterial disease, although evidence for cardiovascular mortality and myocardial infarction is less clear and overall study quality is l…
DOI: 10.1016/j.vph.2014.09.001 -
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy
A comprehensive meta-analysis of 29 randomized trials (266,148 patients) shows that baseline body mass index (BMI) modulates the cardiovascular benefit of intensive LDL-C lowering therapy, with the greatest reductions in cardiovascular and all-cause mortality observed in individ…
DOI: 10.1016/j.amjcard.2019.12.006 -
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy significantly reduces cardiovascular events in both women and men after acute coronary syndrome, with a favorable safety profile.
DOI: 10.1161/JAHA.117.006901 -
What to Believe and Do About Statin-Associated Adverse Effects
This Viewpoint argues that statins' vascular benefits outweigh their rare adverse effects, but clinicians should acknowledge, investigate, and collaboratively manage statin-associated muscle symptoms despite ongoing uncertainty about mild myalgia.
DOI: 10.1001/jama.2016.16557 -
Managing statin-related side effects: should we avoid or overcome them?
Statins provide strong cardiovascular protection with a low rate of significant adverse effects; most statin-associated muscle symptoms are non-pharmacologic or nocebo-driven and can be managed with evidence-based strategies to maintain therapy.
DOI: 10.36011/cpp.2026.8.e2 -
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
This narrative review synthesizes evidence that statin-associated muscle symptoms are largely attributable to the nocebo effect and are frequently manageable with individualized rechallenge and dosing strategies.
DOI: 10.1002/phar.2681 -
Statin Therapy and the Risk of Rhabdomyolysis in Physically Active Individuals: Implications for Sports Medicine
This narrative review synthesizes prior literature on statin-induced rhabdomyolysis, concluding that the condition is rare in trials but more common in real-world settings and that strenuous exercise may amplify statin-related muscle injury in physically active individuals.
DOI: 10.12775/qs.2026.49.67647 -
Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation
This study maps two high-affinity binding sites (Sim-1 and Sim-2) for simvastatin in the skeletal muscle ryanodine receptor RyR1 using cryo-EM and radioligand binding, demonstrates statin-induced RyR1 activation with strand-specific differences from RyR2, shows that a pathogenic…
DOI: 10.1172/JCI194490 -
Statin Therapy for Primary and Secondary Prevention in Older Adults
Evidence supports statin therapy for secondary prevention in older adults and for primary prevention in selected high-risk older patients; age alone should not deter statin therapy.
DOI: 10.1007/s11883-024-01257-9 -
ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC
This paper reviews the 2013 ACC/AHA ASCVD risk calculator (Pooled Cohort Equation) for estimating 10-year risk of hard ASCVD events, discussing its development, validation, performance, limitations (including overestimation in various populations), and clinical use in guiding st…
DOI: 10.65357/001c.154426